Third Line/Rescue HIV Treatment Research

See also: Structured HIV Treatment Interruptions

Hide Archived (Historical) Articles

Management of Treatment-Experienced Patients: A Summary of Key CROI 2008 Research (February 11, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
New Treatment Paradigms for Treatment-Experienced Patients (November 13, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Optimizing Therapy for Patients With Multidrug-Resistant HIV (July 31, 2006)
To read PDF, click here
From Insight Medical Communications Inc.
New Developments in HIV Drug Resistance and Options for Treatment-Experienced Patients (May 15, 2006)
Coverage of the 4th European HIV Drug Resistance Workshop and the 12th Annual Conference of the British HIV Association
Free CME/CE credit available for physicians, nurses and pharmacists.
From The Body PRO
Researchers Examine Use of Artificial Intelligence to Select Ideal Regimens for Treatment-Experienced Patients (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Four-NRTI Regimen May Provide Simple Option for Treatment-Experienced Patients on Unduly Complex or Toxic Treatment (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
[Archived Article]
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
[Archived Article]
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From The Body PRO
Lopinavir/Ritonavir Plus Efavirenz -- Worthy or Wacky? (July/August 2005)
[Archived Article]
A French study examines an NRTI-sparing regimen containing two of the most powerful antiretrovirals.
From The Body PRO
Triple PI Therapy May Help Heavily Treatment-Experienced Patients, But Pill Burden a Concern (October 2004)
[Archived Article]
Quick recap of a study in JAIDS.
In HIV Treatment ALERTS!, from The Center for AIDS
Tenofovir and Efavirenz Show Promise as Two-Drug Maintenance Regimen (July 26, 2004)
[Archived Article]
The so-called "COOL Study" examined this novel two-drug regimen in patients who had already achieved viral suppression on traditional, three-drug HAART.
From aidsmap.com
Intermittent Drug Switching Can Resensitize Patients With Multidrug-Resistant HIV-1 (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
New Dosing Regimen for Ritonavir-Boosted Atazanavir in Treatment-Experienced Patients; Revisions Made to Packaging Insert (July 7, 2004)
From U.S. Food and Drug Administration
Salvage Therapy II Think Tank: Integration of Salvage Research Into Existing Networks and Structures (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Salvage Therapy II Think Tank: Meeting Summary (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Salvage Therapy II Think Tank: Proof of Concept Studies/Translational Research; New Hypotheses (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Salvage Therapy II Think Tank: Regulatory Issues and Challenges in Salvage Therapy (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Salvage Therapy II Think Tank: The Future of Salvage Therapy: Monitoring Systems for Patient Outcomes (Summer 2004)
[Archived Article]
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Little Difference Between Resistance Testing Methods in Treatment-Experienced Patients (February 10, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Single-Drug Interruption May Be Useful in Identifying Still-Active Drugs in Heavily Treated Patients (February 10, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Triple-PI Regimens for Rescue Treatment (February 10, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Boosted Atazanavir Similar to Boosted Lopinavir in Treatment-Experienced Patients (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
Adding ddI Achieves Fall in Viral Load in HAART Patients With Resistance (September 14, 2003)
[Archived Article]
From aidsmap.com
Risk of Death Following Triple-Class Virological Failure (September 14, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
To Switch or Not to Switch: When Is It a Question? (September 2003)
[Archived Article]
Steven Deeks, M.D., offers his wisdom on what options remain for patients who have failed one, two or many HAART regimens.
In The PRN Notebook
Ritonavir-Boosted Atazanavir Demonstrates Comparable Viral Load Reduction to Kaletra (August 15, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
[Archived Article]
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Atazanavir in Treatment-Experienced Patients (July 15, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
[Archived Article]
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Tipranavir/Ritonavir's Resistance Profile in Multiple-Protease-Inhibitor-Experienced Patients (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
An Interview With Dr. Cal Cohen on Highlights From the 10th Conference on Retroviruses and Opportunistic Infections (April 4, 2003)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
Atazanavir Resistance: Use as Second- or Third-Line PI Should Not Be Ruled Out (April 1, 2003)
[Archived Article]
Evidence that this drug in development may be more than a first-line treatment.
From aidsmap.com
Structured Treatment Interruption to Increase Response to Salvage Therapy (Spring 2003)
[Archived Article]
From STEP's conference review of Retrovirus 2003.
In STEP Perspective, from Seattle Treatment Education Project
The Context Study: Efficacy and Safety of GW433908/RTV in PI-Experienced Subjects With Virological Failure (24 Week Results) (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor-Experienced Patients: BI 1182.52 (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Effect of Amprenavir Hypersusceptibility on the Response to APV/Ritonavir-Based Therapy in ART-Experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-Week Data (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor-Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52 (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Pharmacokinetic Parameters of Atazanavir/Ritonavir When Combined to Tenofovir in HIV Infected Patients With Multiple Treatment Failures: A Substudy of Puzzle2-ANRS 107 Trial (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Salvage Strategies and STI at the 10th Annual Retrovirus Conference (January/February 2003)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Safety Profile of Tenofovir DF in Treatment-Experienced Patients From Randomized, Placebo-Controlled Clinical Trials (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
Predictors of Long-Term Response to Therapy Resumption After Treatment Interruption in HIV-1 Infected Patients Failing Antiretroviral Therapy (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
International HIV Workshop on Management of Treatment-Experienced Patients (November 2002)
[Archived Article]
A summary of the workshop's presentations.
In Hopkins HIV Report
Data From the 14th International AIDS Conference: Treatment-Experienced Patients (October 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Expert Opinion From Barcelona: For Experienced Folks (September/October 2002)
[Archived Article]
In Positively Aware, from Test Positive Aware Network
Enfuvirtide in Combination With an Optimized Background Regimen vs. OB Alone in Patients With Prior Experience or Resistance to Each of the Three Classes of Approved Antiretrovirals (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
Dual vs. Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure (July 10, 2002)
[Archived Article]
Adding a second protease inhibitor to a failing regimen brings favorable results, according to a nationwide study.
In Journal of the American Medical Association
Tenofovir DF: A 48-Week Final Analysis From a Phase III Randomized, Double Blind, Placebo Controlled Study in Antiretroviral Treatment-Experienced Patients (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
Preliminary Results of Intensification Therapy With Amprenavir/Ritonavir in Two Different Doses: 1,200/200 QD vs. 600/100 BID in Heavily Pretreated Patients Failing HAART (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
Safety Profile of Tenofovir DF in Antiretroviral Treatment-Experienced Patients From Randomized, Double-Blind, Placebo-Controlled Clinical Trials (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
Successful Intensification of Antiretroviral Therapy With Abacavir in Clinical Practice (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (July 8, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
Anti-HIV Therapy Update: STI and Third-Line Therapy (March 2002)
[Archived Article]
In Project Inform Perspective, from Project Inform
Selected Highlights From Retrovirus: Medications for the Treatment Experienced (February 28, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Efficacy, Safety and Amprenavir: Pharmacokinetic Responses of Twice-Daily APV and Ritonavir Regimens in HIV-1 Infected Treatment-Experienced Adults for 48 Weeks (ESS40006) (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Management of "Salvage" Antiretroviral Therapy (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Antiretroviral Therapy for Previously Treated Patients (December 2001)
[Archived Article]
Summary of an August 2001 New England Journal of Medicine editorial.
In Body Positive, from Body Positive
Efficacy of Lopinavir in Heavily Pretreated Patients (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Antiviral Activity and Tolerability of PEG-Intron in HIV Patients Failing HAART (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Impact of Treatment Interruption on Plasma Viral Load, CD4 Count and Virtual Phenotypes (Virco) in HIV Patients Who Failed Multiple Courses of Antiretroviral Therapy (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
FDA Discusses Trial Design for Salvage Therapy (April 2001)
[Archived Article]
In TAGline, from Treatment Action Group
FDA Gives Salvage Therapy Testing a Push Forward (March 23, 2001)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
Treatment of Antiretroviral-Experienced Patients: New Data From the 8th Retrovirus Conference (March 1, 2001)
[Archived Article]
In Hopkins HIV Report
Amprenavir and Ritonavir: Intra-Individual Comparison of Different Doses and Influence of Concomitant NNRTI on Steady-State Pharmacokinetics in HIV-Infected Patients (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Indinavir/Ritonavir Versus Indinavir in Combination With AZT/3TC for Treatment of HIV in Nucleoside-Experienced Patients: A Randomized, Open-Label Trial (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Randomized Salvage Therapy With Saquinavir-Ritonavir (SQV-RTV) Versus Saquinavir-Nelfinavir (SQV-NFV) for Highly Experienced HIV-Infected Patients (September 17, 2000)
[Archived Article]
In The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
New Drugs for the Treatment-Experienced Patient (September 2000)
[Archived Article]
In The PRN Notebook
Forty-Eight Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage (July 13, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
Prospective, Multicenter Study of ddI Plus Hydroxyurea Plus Efavirenz Plus Protease Inhibitor Salvage Therapy. One-Year of Follow-Up. (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
Response to Salvage With Efavirenz: Implications for Sequencing Antiretroviral Therapy (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
Responses to Salvage Combination Therapy With Efavirenz in Patients With HIV Who Have Failed Antiretroviral Therapy With a Protease Inhibitor (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
The Combination of Ritonavir and Amprenavir in Salvage Regimens Overcomes Clinically Multiple-Drug Resistant HIV (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
ABT-378/Ritonavir and Efavirenz for Salvage Therapy in Patients Multiply-Exposed to PIs (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
Therapeutic Drug Monitoring of Amprenavir Combined With Ritonavir as Salvage Therapy in HIV-1-Infected Patients (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
Conference Coverage: 3rd International Workshop on Salvage Therapy for HIV Infection (Summer 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Advances in Research: Second & Third Line Therapy (September 1999)
[Archived Article]
In Project Inform Perspective, from Project Inform
Randomized Trial of Abacavir in Combination with Indinavir and Efavirenz in HIV-Infected Patients with NRTI Experience (February 4, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Efficacy of the Combination of Stavudine (d4T), Didanosine (ddI), and Nevirapine (NVP) as Initial Antiretroviral Therapy and Following Treatment with HIV-1 Protease Inhibitors (June 30, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
Combination d4T and 3TC in Patients with Prior Exposure (February 1998)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
Double Protease Inhibitor Combinations (September 28-October 1, 1997)
[Archived Article]
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
A Study to Evaluate the Clinical and Virologic Efficacy of a Crixivan, DDI, and D4T Combination (September 1997)
[Archived Article]
In The 35th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Druthers, Grim: Tales of Multiply Resistant HIV (February 7, 1997)
[Archived Article]
From Treatment Action Group
Ritonavir-Saquinavir Combination Therapy in Patients with Advanced HIV Infection (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Viral Resistance (report from the XIth International AIDS Conference) (Summer 1996)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project
More Data on Higher-Dose Lopinavir/Ritonavir (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO